Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results

Keywords

Hematology ×

Lymphoma ×

Show more Keywords

Table of contents

Select data models

Selected data models

You must log in to select data models for download or further analysis.

69 Search results.

Eligibility Lymphoma NCT00290498

- 9/27/21 - 1 form, 2 itemgroups, 15 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290498

Eligibility Lymphoma, Large-Cell, Anaplastic NCT00866047

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00866047

Eligibility Lymphoma NCT02056548

- 9/20/21 - 1 form, 2 itemgroups, 12 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02056548

Eligibility Lymphoma NCT02392039

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Patient Enrollment/ Patient Eligibility - Demographics; General Medical History; Prior Therapy; History of Lymphoma

- 3/18/21 - 1 form, 13 itemgroups, 46 items, 1 language

Itemgroups: Administrative,Demographics (Enrollment),Investigator Signature,For Coulter Use Only,Demographics (General Medical History),Medical History Date,General Medical History,Prior Therapy,Prior Radiation Therapy,History of Lymphoma,Lymphoma Cell Type,Lymphoma Grade ,History of Lymphoma

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Swedish National Quality Registry for Lymphoma (Nationellt kvalitetsregister för lymfom) - Registration form and cancer report (Anmälningsblankett och canceranmälan)

- 3/15/21 - 1 form, 5 itemgroups, 82 items, 1 language

Itemgroups: Administrative Data,Diagnosis,Primary Treatment,Disease Stage,Prognostic factors

Part of Swedish National Quality Registry for Blood Cancer source: https://www.cancercentrum.se/samverkan/cancerdiagnoser/blod-lymfom-myelom/lymfom-lymfkortelcancer/kvalitetsregister/ Leader of Registry: Karin Ekström Smedby, Karolinska Universitetssjukhuset Solna Chairman: Mats Jerkeman, Skånes universitetssjukhus, mats.jerkeman@skane.se This Registration form is valid from 2012-03-15. The form must be completed and submitted shortly after completion of the investigation to the Regional Cancer Center (Regionalt Cancercentrum).

Swedish National Quality Registry for Lymphoma (Nationellt kvalitetsregister för lymfom) - Primary Treatment (Primärbehandling)

- 3/15/21 - 1 form, 5 itemgroups, 54 items, 1 language

Itemgroups: Administrative Data,Diagnosis,Primary Treatment,Completed primary treatment,Additional Treatment (Complementary to primary treatment)

Part of Swedish National Quality Registry for Blood Cancer source: https://www.cancercentrum.se/samverkan/cancerdiagnoser/blod-lymfom-myelom/lymfom-lymfkortelcancer/kvalitetsregister/ Leader of Registry: Karin Ekström Smedby, Karolinska Universitetssjukhuset Solna Chairman: Mats Jerkeman, Skånes Universitetssjukhus, mats.jerkeman@skane.se This Primary Treatment form is valid from 2012-03-15. The form must be completed and submitted after completion of treatment or at the latest 1 year after diagnosis to: Regional Cancer Center in the respective region. If active tumor treatment is not given, the form must be filled in every two years until treatment is given.

Eligibility Lymphoma NCT01831505

- 7/18/20 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents; ODM derived from: https://clinicaltrials.gov/show/NCT01831505

Eligibility Lymphoma NCT01590732

- 7/18/20 - 1 form, 2 itemgroups, 15 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01590732

Eligibility Lymphoma NCT01410630

- 7/18/20 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01410630

Eligibility Lymphoma NCT01751412

- 7/17/20 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Proton Radiation for Lymphoma Involving Mediastinum; ODM derived from: https://clinicaltrials.gov/show/NCT01751412

Eligibility Lymphoma NCT01473628

- 7/16/20 - 1 form, 2 itemgroups, 19 items, 1 language

Itemgroups: Inclusion Criteria,Exclusion Criteria

Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01473628

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.